IBDEI04V ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6241,1,2,0)
 ;;=2^Fundus Photography
 ;;^UTILITY(U,$J,358.3,6241,1,3,0)
 ;;=3^92250
 ;;^UTILITY(U,$J,358.3,6242,0)
 ;;=66030^^50^447^5^^^^1
 ;;^UTILITY(U,$J,358.3,6242,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6242,1,2,0)
 ;;=2^Inj Treatment of Eye,Medication
 ;;^UTILITY(U,$J,358.3,6242,1,3,0)
 ;;=3^66030
 ;;^UTILITY(U,$J,358.3,6243,0)
 ;;=67028^^50^447^6^^^^1
 ;;^UTILITY(U,$J,358.3,6243,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6243,1,2,0)
 ;;=2^Intravitreal Inj of Eye Drug
 ;;^UTILITY(U,$J,358.3,6243,1,3,0)
 ;;=3^67028
 ;;^UTILITY(U,$J,358.3,6244,0)
 ;;=67500^^50^447^10^^^^1
 ;;^UTILITY(U,$J,358.3,6244,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6244,1,2,0)
 ;;=2^Retrobulbar Inj,Medication
 ;;^UTILITY(U,$J,358.3,6244,1,3,0)
 ;;=3^67500
 ;;^UTILITY(U,$J,358.3,6245,0)
 ;;=67505^^50^447^9^^^^1
 ;;^UTILITY(U,$J,358.3,6245,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6245,1,2,0)
 ;;=2^Retrobulbar Inj,Alcohol
 ;;^UTILITY(U,$J,358.3,6245,1,3,0)
 ;;=3^67505
 ;;^UTILITY(U,$J,358.3,6246,0)
 ;;=68200^^50^447^13^^^^1
 ;;^UTILITY(U,$J,358.3,6246,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6246,1,2,0)
 ;;=2^Subconjunctival Injection
 ;;^UTILITY(U,$J,358.3,6246,1,3,0)
 ;;=3^68200
 ;;^UTILITY(U,$J,358.3,6247,0)
 ;;=96372^^50^447^11^^^^1
 ;;^UTILITY(U,$J,358.3,6247,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6247,1,2,0)
 ;;=2^SC/IM Injection
 ;;^UTILITY(U,$J,358.3,6247,1,3,0)
 ;;=3^96372
 ;;^UTILITY(U,$J,358.3,6248,0)
 ;;=96402^^50^447^12^^^^1
 ;;^UTILITY(U,$J,358.3,6248,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6248,1,2,0)
 ;;=2^SQ/IM Anti-Neplastic Hormone Inj
 ;;^UTILITY(U,$J,358.3,6248,1,3,0)
 ;;=3^96402
 ;;^UTILITY(U,$J,358.3,6249,0)
 ;;=C9257^^50^447^2^^^^1
 ;;^UTILITY(U,$J,358.3,6249,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6249,1,2,0)
 ;;=2^Bevacizumab Inj 0.25mg
 ;;^UTILITY(U,$J,358.3,6249,1,3,0)
 ;;=3^C9257
 ;;^UTILITY(U,$J,358.3,6250,0)
 ;;=J1094^^50^447^4^^^^1
 ;;^UTILITY(U,$J,358.3,6250,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6250,1,2,0)
 ;;=2^Dexamethasone Acetate Inj per 1mg
 ;;^UTILITY(U,$J,358.3,6250,1,3,0)
 ;;=3^J1094
 ;;^UTILITY(U,$J,358.3,6251,0)
 ;;=J2778^^50^447^8^^^^1
 ;;^UTILITY(U,$J,358.3,6251,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6251,1,2,0)
 ;;=2^Ranibizumab Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,6251,1,3,0)
 ;;=3^J2778
 ;;^UTILITY(U,$J,358.3,6252,0)
 ;;=J3300^^50^447^14^^^^1
 ;;^UTILITY(U,$J,358.3,6252,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6252,1,2,0)
 ;;=2^Triescence Inj per 1mg
 ;;^UTILITY(U,$J,358.3,6252,1,3,0)
 ;;=3^J3300
 ;;^UTILITY(U,$J,358.3,6253,0)
 ;;=J3301^^50^447^7^^^^1
 ;;^UTILITY(U,$J,358.3,6253,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6253,1,2,0)
 ;;=2^Kenalog Inj per 10mg
 ;;^UTILITY(U,$J,358.3,6253,1,3,0)
 ;;=3^J3301
 ;;^UTILITY(U,$J,358.3,6254,0)
 ;;=J3396^^50^447^15^^^^1
 ;;^UTILITY(U,$J,358.3,6254,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6254,1,2,0)
 ;;=2^Verteporfin Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,6254,1,3,0)
 ;;=3^J3396
 ;;^UTILITY(U,$J,358.3,6255,0)
 ;;=J9035^^50^447^3^^^^1
 ;;^UTILITY(U,$J,358.3,6255,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6255,1,2,0)
 ;;=2^Bevacizumab Inj 10mg
 ;;^UTILITY(U,$J,358.3,6255,1,3,0)
 ;;=3^J9035
 ;;^UTILITY(U,$J,358.3,6256,0)
 ;;=J0178^^50^447^1^^^^1
 ;;^UTILITY(U,$J,358.3,6256,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6256,1,2,0)
 ;;=2^Aflibercept Inj 1mg
 ;;^UTILITY(U,$J,358.3,6256,1,3,0)
 ;;=3^J0178
 ;;^UTILITY(U,$J,358.3,6257,0)
 ;;=67028^^50^448^1^^^^1
 ;;^UTILITY(U,$J,358.3,6257,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6257,1,2,0)
 ;;=2^Intravitreal Inj of Eye Drug
 ;;^UTILITY(U,$J,358.3,6257,1,3,0)
 ;;=3^67028
 ;;^UTILITY(U,$J,358.3,6258,0)
 ;;=J9035^^50^448^3^^^^1
 ;;^UTILITY(U,$J,358.3,6258,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6258,1,2,0)
 ;;=2^Bevacizumab Inj 10mg
 ;;^UTILITY(U,$J,358.3,6258,1,3,0)
 ;;=3^J9035
 ;;^UTILITY(U,$J,358.3,6259,0)
 ;;=J2778^^50^448^5^^^^1
 ;;^UTILITY(U,$J,358.3,6259,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6259,1,2,0)
 ;;=2^Ranibizumab Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,6259,1,3,0)
 ;;=3^J2778
 ;;^UTILITY(U,$J,358.3,6260,0)
 ;;=J3301^^50^448^4^^^^1
 ;;^UTILITY(U,$J,358.3,6260,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6260,1,2,0)
 ;;=2^Kenalog Inj per 10mg
 ;;^UTILITY(U,$J,358.3,6260,1,3,0)
 ;;=3^J3301
 ;;^UTILITY(U,$J,358.3,6261,0)
 ;;=J0178^^50^448^2^^^^1
 ;;^UTILITY(U,$J,358.3,6261,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,6261,1,2,0)
 ;;=2^Aflibercept Inj 1mg
 ;;^UTILITY(U,$J,358.3,6261,1,3,0)
 ;;=3^J0178
 ;;^UTILITY(U,$J,358.3,6262,0)
 ;;=373.32^^51^449^48
 ;;^UTILITY(U,$J,358.3,6262,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6262,1,3,0)
 ;;=3^Eyelid,Dermatitis,Allergic
 ;;^UTILITY(U,$J,358.3,6262,1,4,0)
 ;;=4^373.32
 ;;^UTILITY(U,$J,358.3,6262,2)
 ;;=^269061
 ;;^UTILITY(U,$J,358.3,6263,0)
 ;;=373.00^^51^449^4
 ;;^UTILITY(U,$J,358.3,6263,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6263,1,3,0)
 ;;=3^Blepharitis
 ;;^UTILITY(U,$J,358.3,6263,1,4,0)
 ;;=4^373.00
 ;;^UTILITY(U,$J,358.3,6263,2)
 ;;=Blepharitis^15271
 ;;^UTILITY(U,$J,358.3,6264,0)
 ;;=373.2^^51^449^7
 ;;^UTILITY(U,$J,358.3,6264,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6264,1,3,0)
 ;;=3^Chalazion
 ;;^UTILITY(U,$J,358.3,6264,1,4,0)
 ;;=4^373.2
 ;;^UTILITY(U,$J,358.3,6264,2)
 ;;=^22156
 ;;^UTILITY(U,$J,358.3,6265,0)
 ;;=374.84^^51^449^29
 ;;^UTILITY(U,$J,358.3,6265,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6265,1,3,0)
 ;;=3^Eyelid Cysts
 ;;^UTILITY(U,$J,358.3,6265,1,4,0)
 ;;=4^374.84
 ;;^UTILITY(U,$J,358.3,6265,2)
 ;;=^269119
 ;;^UTILITY(U,$J,358.3,6266,0)
 ;;=374.87^^51^449^31
 ;;^UTILITY(U,$J,358.3,6266,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6266,1,3,0)
 ;;=3^Eyelid Dermatochalasis
 ;;^UTILITY(U,$J,358.3,6266,1,4,0)
 ;;=4^374.87
 ;;^UTILITY(U,$J,358.3,6266,2)
 ;;=^269123
 ;;^UTILITY(U,$J,358.3,6267,0)
 ;;=375.15^^51^449^12
 ;;^UTILITY(U,$J,358.3,6267,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6267,1,3,0)
 ;;=3^Dry Eye Syndrome
 ;;^UTILITY(U,$J,358.3,6267,1,4,0)
 ;;=4^375.15
 ;;^UTILITY(U,$J,358.3,6267,2)
 ;;=Dry Eye Syndrome^37168
 ;;^UTILITY(U,$J,358.3,6268,0)
 ;;=374.01^^51^449^20
 ;;^UTILITY(U,$J,358.3,6268,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6268,1,3,0)
 ;;=3^Entropion, Senile
 ;;^UTILITY(U,$J,358.3,6268,1,4,0)
 ;;=4^374.01
 ;;^UTILITY(U,$J,358.3,6268,2)
 ;;=Entropion, Senile^269074
 ;;^UTILITY(U,$J,358.3,6269,0)
 ;;=375.20^^51^449^68
 ;;^UTILITY(U,$J,358.3,6269,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6269,1,3,0)
 ;;=3^Lacrimal,Epiphora
 ;;^UTILITY(U,$J,358.3,6269,1,4,0)
 ;;=4^375.20
 ;;^UTILITY(U,$J,358.3,6269,2)
 ;;=Epiphora^269136
 ;;^UTILITY(U,$J,358.3,6270,0)
 ;;=373.11^^51^449^63
 ;;^UTILITY(U,$J,358.3,6270,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6270,1,3,0)
 ;;=3^Hordeolum Externum
 ;;^UTILITY(U,$J,358.3,6270,1,4,0)
 ;;=4^373.11
 ;;^UTILITY(U,$J,358.3,6270,2)
 ;;=^58510
 ;;^UTILITY(U,$J,358.3,6271,0)
 ;;=373.12^^51^449^64
 ;;^UTILITY(U,$J,358.3,6271,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6271,1,3,0)
 ;;=3^Hordeolum Internum
 ;;^UTILITY(U,$J,358.3,6271,1,4,0)
 ;;=4^373.12
 ;;^UTILITY(U,$J,358.3,6271,2)
 ;;=^58512
 ;;^UTILITY(U,$J,358.3,6272,0)
 ;;=216.1^^51^449^54
 ;;^UTILITY(U,$J,358.3,6272,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6272,1,3,0)
 ;;=3^Eyelid/Canthus,Benign Neopl
 ;;^UTILITY(U,$J,358.3,6272,1,4,0)
 ;;=4^216.1
 ;;^UTILITY(U,$J,358.3,6272,2)
 ;;=Neoplasm, Benign of Lid^267630
 ;;^UTILITY(U,$J,358.3,6273,0)
 ;;=374.30^^51^449^43
 ;;^UTILITY(U,$J,358.3,6273,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6273,1,3,0)
 ;;=3^Eyelid Ptosis,Unspec
 ;;^UTILITY(U,$J,358.3,6273,1,4,0)
 ;;=4^374.30
 ;;^UTILITY(U,$J,358.3,6273,2)
 ;;=^15283
 ;;^UTILITY(U,$J,358.3,6274,0)
 ;;=375.30^^51^449^9
 ;;^UTILITY(U,$J,358.3,6274,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6274,1,3,0)
 ;;=3^Dacryocystitis
 ;;^UTILITY(U,$J,358.3,6274,1,4,0)
 ;;=4^375.30
 ;;^UTILITY(U,$J,358.3,6274,2)
 ;;=Dacrocystitis^30880
 ;;^UTILITY(U,$J,358.3,6275,0)
 ;;=921.1^^51^449^28
 ;;^UTILITY(U,$J,358.3,6275,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6275,1,3,0)
 ;;=3^Eyelid Contusion
 ;;^UTILITY(U,$J,358.3,6275,1,4,0)
 ;;=4^921.1
 ;;^UTILITY(U,$J,358.3,6275,2)
 ;;=^275367
 ;;^UTILITY(U,$J,358.3,6276,0)
 ;;=374.51^^51^449^46
 ;;^UTILITY(U,$J,358.3,6276,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6276,1,3,0)
 ;;=3^Eyelid Xanthelasma
 ;;^UTILITY(U,$J,358.3,6276,1,4,0)
 ;;=4^374.51
 ;;^UTILITY(U,$J,358.3,6276,2)
 ;;=^269107
 ;;^UTILITY(U,$J,358.3,6277,0)
 ;;=374.11^^51^449^15
 ;;^UTILITY(U,$J,358.3,6277,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6277,1,3,0)
 ;;=3^Ectropion, Senile
 ;;^UTILITY(U,$J,358.3,6277,1,4,0)
 ;;=4^374.11
 ;;^UTILITY(U,$J,358.3,6277,2)
 ;;=Ectropion, Senile^269083
 ;;^UTILITY(U,$J,358.3,6278,0)
 ;;=333.81^^51^449^6
 ;;^UTILITY(U,$J,358.3,6278,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6278,1,3,0)
 ;;=3^Blepharospasm
 ;;^UTILITY(U,$J,358.3,6278,1,4,0)
 ;;=4^333.81
 ;;^UTILITY(U,$J,358.3,6278,2)
 ;;=Blepharospasm^15293
 ;;^UTILITY(U,$J,358.3,6279,0)
 ;;=351.8^^51^449^62
 ;;^UTILITY(U,$J,358.3,6279,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6279,1,3,0)
 ;;=3^Hemifacial Spasm
 ;;^UTILITY(U,$J,358.3,6279,1,4,0)
 ;;=4^351.8
 ;;^UTILITY(U,$J,358.3,6279,2)
 ;;=Hemifacial Spasm^87589
 ;;^UTILITY(U,$J,358.3,6280,0)
 ;;=374.10^^51^449^17
 ;;^UTILITY(U,$J,358.3,6280,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6280,1,3,0)
 ;;=3^Ectropion, Unspecified
 ;;^UTILITY(U,$J,358.3,6280,1,4,0)
 ;;=4^374.10
 ;;^UTILITY(U,$J,358.3,6280,2)
 ;;=Ectropion, Unspecified^38326
 ;;^UTILITY(U,$J,358.3,6281,0)
 ;;=374.14^^51^449^13
 ;;^UTILITY(U,$J,358.3,6281,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6281,1,3,0)
 ;;=3^Ectropion, Cicatricial
 ;;^UTILITY(U,$J,358.3,6281,1,4,0)
 ;;=4^374.14
 ;;^UTILITY(U,$J,358.3,6281,2)
 ;;=Edctropion, Cicatricial^269089
 ;;^UTILITY(U,$J,358.3,6282,0)
 ;;=374.12^^51^449^14
